✦ LIBER ✦

Epidermal Growth Factor Receptor Inhibitors, Gefitinib and Erlotinib (Tarceva™, OSI-774), in the Treatment of Bronchioloalveolar Carcinoma

✍ Scribed by Heather DeGrendele; Chandra P. Belani; Michael C. Perry

Book ID: 114411929
Publisher: CIG Media Group, LP.
Year: 2003
Tongue: English
Weight: 88 KB
Volume: 5
Category: Article
ISSN: 1525-7304
DOI: 10.1016/s1525-7304(11)70324-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-188 Encouraging activity and durable r

O-188 Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinoma

✍ Patel, Jyoti D.; Miller, Vincent A.; Kris, Mark G.; Shah, Neelam T.; Pizzo, Barb 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 187 KB

Erlotinib (OSI-774, Tarceva™), a Selecti

Erlotinib (OSI-774, Tarceva™), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Chemotherapy for Advanced Non–Small-Cell Lung Cancer

✍ Mary Hightower; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 78 KB

Phase I, pharmacokinetic (PK), and biolo

Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 (Erlotinib or Tarceva) in combination with docetaxel

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 139 KB

54 The epidermal growth factor receptor

54 The epidermal growth factor receptor tyrosine kinase inhibitor, eriotinib (Tarceva TM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: interim results of a phase II trial

✍ J. Patel; V. Miller; M. Kris; N. Shah; L. Tyson; B. Pizzo; M. Zakowski; M. Cespo 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Targeting the epidermal growth factor re

Targeting the epidermal growth factor receptor by erlotinib (Tarceva™) for the treatment of esophageal cancer

✍ Andreas P. Sutter; Michael Höpfner; Alexander Huether; Kerstin Maaser; Hans Sche 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 370 KB 👁 1 views

## Abstract Esophageal cancer is the sixth most common cause of cancer‐related death worldwide. Because of very poor 5‐year survival new therapeutic approaches are mandatory. Erlotinib (Tarceva™), an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR‐TK), potently suppresses the gr

Phase II Clinical Trial Data with the Ep

Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer

✍ Romàn Pérez-Soler 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 144 KB